Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,871 recruiting studies in this area right now.
By phase
- Not applicable4,905
- Phase 21,176
- Phase 1584
- Phase 3468
- Phase 1/Phase 2390
- Phase 4235
- Phase 2/Phase 3113
Top conditions
- Colorectal Cancer496
- Gastric Cancer297
- Pancreatic Cancer294
- Hepatocellular Carcinoma283
- Esophageal Cancer191
- Rectal Cancer174
- Breast Cancer146
- Crohn Disease144
- Ulcerative Colitis141
- Colon Cancer113
- Inflammatory Bowel Diseases108
- Hepatocellular Carcinoma (HCC)102
- Liver Cancer99
- Lung Cancer98
- Pancreas Cancer94
- Ovarian Cancer90
- Esophageal Squamous Cell Carcinoma87
- Cystic Fibrosis78
Leading sponsors
- Fudan University104
- Sun Yat-sen University89
- Mayo Clinic75
- Chinese University of Hong Kong60
- M.D. Anderson Cancer Center59
- Second Affiliated Hospital, School of Medicine, Zhejiang University57
- Assistance Publique - Hôpitaux de Paris55
- Sixth Affiliated Hospital, Sun Yat-sen University50
- National Taiwan University Hospital49
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences48
Where studies are running
- California464
- Arizona175
- Texas146
- Florida134
- Massachusetts128
- New York123
- Alabama121
- Maryland86
- Ohio78
- Pennsylvania72
Recruiting studies7,871 total
- NCT07700381Recruiting
Fermented dairy and gut bacteria study
This study tests if a fermented dairy product can increase the amount of a healthy gut bacteria called Bifidobacterium. If you are healthy, age 45-60, and willing to follow the diet rules, you may be able to join.
DijonAges 45–60 - NCT07654751RecruitingPhase 4
Study of Tremfya in breast milk of breastfeeding women
This study measures how much Tremfya (guselkumab) gets into breast milk for women who are already taking it for conditions like psoriasis or arthritis and choose to breastfeed. It helps understand if the drug passes to the baby.
Chapel Hill, North CarolinaAges 18 years+ - NCT07027826Recruiting
String test for eosinophilic esophagitis in African patients
This study tests a new, less invasive way (the Esophageal String Test) to look for signs of eosinophilic esophagitis—an allergic condition that can make swallowing painful or difficult. It is for people of African descent who have trouble swallowing and are already having an endoscopy.
Bethesda, MarylandAges 18–65 - NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Anaheim, CaliforniaAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Gilbert, ArizonaAges 18–75 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Dothan, AlabamaAges 18–75 - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT07793487Enrolling by invitation
Testing a special dairy drink for gut and metabolic health
This study tests whether a special dairy product can help improve symptoms in people with irritable bowel syndrome or early signs of metabolic syndrome. Participants must be at a healthy weight and not have other major health conditions or be on certain diets.
WarsawAges 18 years+ - NCT07782164Recruiting
Irreversible electroporation for recurrent pelvic tumors
This study tests a new technique called irreversible electroporation (IRE) for treating pelvic tumors that have returned despite earlier treatment. IRE uses electrical pulses to destroy cancer cells without surgery, offering a potential option when other local treatments like surgery or radiation are not suitable.
Amsterdam, North HollandAges 18 years+ - NCT06788444Recruiting
Esketamine for irritable bowel syndrome with anxiety or depression
This study tests if esketamine, a fast-acting medication, can help people with irritable bowel syndrome who also have anxiety or depression. It is given during a colonoscopy to see if it reduces your IBS symptoms.
Beijing, Beijing MunicipalityAges 18–60 - NCT07562152RecruitingPhase 3
Atebimetinib Plus Gemcitabine/Nab-Paclitaxel for New Pancreatic Cancer
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
Huntsville, AlabamaAges 18 years+ - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT06663319RecruitingPhase 1
Study of JNJ-89402638 for metastatic colorectal and gastric cancers
This trial tests a new drug, JNJ-89402638, alone or with other treatments for people with metastatic colorectal or gastric cancer that has progressed after standard therapies. It aims to find safe and effective doses and combinations.
Tucson, ArizonaAges 18 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Chandler, ArizonaAges 18 years+ - NCT06529718RecruitingPhase 2
Ivonescimab vs FOLFOX for advanced bile duct cancer
This trial tests a new drug, ivonescimab, compared to standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has progressed after initial treatment. It aims to see if ivonescimab can help control the cancer better.
AmiensAges 18 years+ - NCT07293650RecruitingPhase 3
Precision medicine for achalasia treatment study
This trial compares different treatments for achalasia or related swallowing problems. It aims to find the best personalized approach to improve your symptoms.
Scottsdale, ArizonaAges 18 years+ - NCT04485286RecruitingTeam says not enrollingPhase 2
PET scan tracer to find lung or pancreas radiation injury
This Phase 2 study tests a special PET scan tracer to help doctors spot tissue damage after radiation treatment in people with certain lung or pancreatic cancers. The goal is to improve detection and planning around chemoradiation and surgery.
Boston, MassachusettsAges 18–80 - NCT06880055RecruitingTeam says not enrolling
Shield blood test for colorectal cancer screening
This study is testing the Shield blood test for people at average risk of colorectal cancer. It looks at how well the test works for screening, so you can learn about your risk with a simple blood draw.
Chandler, ArizonaAges 45–81 - NCT05183165RecruitingTeam says not enrolling
Study measures copper levels in breast milk for Wilson’s disease
This study measures how much copper is present in breast milk in people with Wilson’s disease. It aims to provide safer guidance for breastfeeding during treatment, including during pregnancy.
ParisAges 18 years+ - NCT06938282RecruitingPhase 2
Study of HRS-4642 with immunotherapy and chemo for pancreatic cancer
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04589468Recruiting
Exercise for cancer survivors at high risk
This study tests whether a structured exercise program can help prevent cancer from coming back in people who have been treated for certain solid tumors (colorectal, ovarian, lung, or breast cancer). If you've completed surgery and adjuvant therapy within the past 2 years and are currently not exercising much, you may be eligible. Participation involves following an exercise plan and regular check-ins.
Durate, CaliforniaAges 18 years+ - NCT07789210RecruitingPhase 2
Neoadjuvant targeted therapy for BRAF-mutant colorectal cancer
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06337695RecruitingPhase 2/Phase 3
Preventing immunotherapy-related diarrhea in advanced cancer
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
Calgary, AlbertaAges 18 years+ - NCT07790510RecruitingPhase 1/Phase 2
Study of HSK42360 with cetuximab for BRAF-mutated colorectal cancer
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
BeijingAges 18 years+
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,871 recruiting gastroenterology studies from the U.S. registry right now, out of 12,272 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.